WntResearch: WntResearch has submitted phase 1b study application

WntResearch today announces that an application regarding permission
to start the Foxy-5 clinical phase 1b study has been submitted to the
Danish Health Authorities.

Nils Brünner, CEO: "This is a very important milestone for
WntResearch. I feel confident that the phase 1b study will provide us
with the information needed to optimize conditions for the pivotal
clinical phase 2 study. The major difference between the phase 1 and
1b studies and the phase 2 study lies in the recruitment of patients.
The phase 1 and 1b studies recruit patients who already have
metastatic disease and for whom the treating oncologist has no more
routine systemic treatment to offer. On the contrary, the phase 2
study will recruit only newly operated cancer patients with no signs
of persistent metastatic lesions. Thus, the phase 2 study will give
us the final answer to the anti-metastatic efficacy of Foxy-5."

For additional information please contact:
Nils Brünner, CEO
E-mail: nbr@wntresearch.com
Telephone: + 45 2614 4708

About WntResearch
WntResearch AB is a public company on the AktieTorget in Sweden.
WntResearch develops the anti-cancer compound Foxy-5 to be used to
combat the metastatic process of cancer. WntResearch has one drug
candidate in clinical phase 1 - Foxy-5 - as well as one candidate
drug in preclinical development - Box-5. The Company is currently
focusing mainly on the development of Foxy-5.

-----------------------------------------------------------
http://news.cision.com/wntresearch/r/wntresearch-has-submitted-phase-1b-...
http://mb.cision.com/Main/11610/9884135/456579.pdf